Research & Publications
Dr. Brown's research has focused on the renin-angiotensin-aldosterone system, leading to discoveries on how that system affects glucose homeostasis, as well as fibrinolysis; the cardiovascular and renal effects of ACE inhibitors and other drugs used to control blood pressure; and the mechanisms of angioedema.
Extensive Research Description
- Role of the renin-angiotensin-aldosterone system in modulating oxidative stress, inflammation and fibrinolysis. The renin-angiotensin-aldosterone system (RAAS) is one of the major blood pressure regulating systems in the body. The small peptide angiotensin II, Ang II, raises blood pressure by constricting blood vessels and increasing salt retention, in part by stimulating synthesis of the mineralocorticoid aldosterone. We now understand that the RAAS has other detrimental effects on the blood vessels, heart and kidney. Both Ang II and aldosterone cause inflammation and fibrosis and promote clotting. Studies in our laboratory have examined the mechanisms of these effects.
- Role of the renin-angiotensin-aldosterone system in regulating glucose homeostasis. Sixty per cent of Americans are obese and both the activity of the RAAS and inflammation are increased in obesity. Obese individuals are at increased risk for the development of diabetes and hypertension, but drugs that interrupt the RAAS seem to decrease this risk. Studies in our laboratory have helped elucidate the mechanism for this effect in order to devise better strategies to prevent diabetes.
- Cardiovascular effects of the kallikrein-kinin system. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are the two major classes of drugs currently used to interrupt the renin-angiotensin-aldosterone system. ACE inhibitors decrease the formation of Ang II, whereas ARBs block the effect of Ang II at its major receptor. In addition, ACE inhibitors prevent the breakdown of and promote the actions of bradykinin, a peptide in the body that lowers blood pressure. Bradykinin has other beneficial effects, like increasing tissue-type plasminogen activator from the endothelium. Bradykinin can also have detrimental effects, promoting inflammation. The net beneficial or detrimental effect of bradykinin may depend on the health of the blood vessels.
- Role of arachidonic acid monooxygenases and epoxygenases in the regulation of blood pressure and cardiovascular risk. Bradykinin exerts its blood pressure lowering effects, in part, through effects on cytochrome P450 (CYP450) epoxygenases that form eicosatetraenoic acids (EETs) from arachidonic acid. EETs relax blood vessels. EETs formed in the kidney also stimulate salt excretion. Animal studies suggest that, in the kidney, EET formation is regulated in part by 20-hydroxyeicosatetraenoic acid 20-HETE, the product of CYP4A11. Research in our laboratory found that a loss-of-function variant of the gene encoding CYP4A11 is associated with high blood pressure and progression of renal disease. This has helped refine our understanding of how these systems regulate blood pressure in humans and how they interact with the RAAS.
- Contribution of peptidases to angiotensin-converting enzyme (ACE) inhibitor-associated angioedema. Despite the many beneficial effects of ACE inhibitors, this class of medications can cause swelling of the lips, tongue, or face, a side effect called angioedema. Likely, this side effect results from decreased breakdown of bradykinin and another peptide called substance P. We have determined groups of patients who are at increased risk for angioedema. Studies in our laboratory have identified one pathway involved in angioedema, allowing us to better predict risk and prevent the side effect.
- Pharmacogenetics of the renin-angiotensin-aldosterone and kallikrein-kinin sytems. Genetic factors modulate all of the processes described above. One goal of our laboratory has been to identify these factors in order to better predict individual responses to drugs such as ACE inhibitors, ARBs, aldosterone receptor blockers and renin inhibitors.
Angioedema; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Fibrinolysis; Hypertension; Inflammation; Kallikreins; Renin-Angiotensin System
- Chapter 35 Education, Training and Career Choices Training Basic, Clinical, and Translational InvestigatorsHartmann K, Heitman E, Brown N. Chapter 35 Education, Training and Career Choices Training Basic, Clinical, and Translational Investigators 2017, 637-647. DOI: 10.1016/b978-0-12-802101-9.00035-1.
- Training basic, clinical, and translational scientists.Hartmann, K.E., Heitman, E., and N.J. Brown. Training basic, clinical, and translational scientists. In Principles of Clinical and Translational Science, 2nd edition, eds. D. Robertson and G.H. Williams, Elsevier, London, UK, 2016, pp. 637-647.
- Correction: Epistatic Interactions in Genetic Regulation of t-PA and PAI-1 Levels in a Ghanaian PopulationPenrod N, Poku K, Vaughn D, Asselbergs F, Brown N, Moore J, Williams S. Correction: Epistatic Interactions in Genetic Regulation of t-PA and PAI-1 Levels in a Ghanaian Population PLOS ONE 2011, 6: 10.1371/annotation/2501cac9-f313-406f-919b-314f12b43516. PMCID: PMC3040063, DOI: 10.1371/annotation/2501cac9-f313-406f-919b-314f12b43516.
- Training basic, clinical, and translational scientists.Hartmann, K.E., Heitman, E., and N.J. Brown. Training basic, clinical, and translational scientists. In Principles of Clinical and Translational Science, eds. D. Robertson and G.H. Williams, Elsevier, London, UK, 2009, pp. 191-200.
- Chapter 13 Training Basic, Clinical and Translational InvestigatorsHartmann K, Heitman E, Brown N. Chapter 13 Training Basic, Clinical and Translational Investigators 2009, 191-199. DOI: 10.1016/b978-0-12-373639-0.00013-3.
- Les effets secondaires aigus des inhibiteurs de l’enzyme de conversion de l’angiotensine dont l’angioœdème, différents dans leur étiologie clinique, partagent une physiopathologie semblableDésormeaux A, Byrd J, Brown N, Adam A. Les effets secondaires aigus des inhibiteurs de l’enzyme de conversion de l’angiotensine dont l’angioœdème, différents dans leur étiologie clinique, partagent une physiopathologie semblable Revue Française D'Allergologie Et D'Immunologie Clinique 2008, 48: 434-440. DOI: 10.1016/j.allerg.2008.02.003.
- Response to Letter Regarding Article, “Plasminogen Activator Inhibitor-1 as a Predictor of Postoperative Atrial Fibrillation After Cardiopulmonary Bypass”Pretorius M, Donahue B, Yu C, Greelish J, Roden D, Brown N. Response to Letter Regarding Article, “Plasminogen Activator Inhibitor-1 as a Predictor of Postoperative Atrial Fibrillation After Cardiopulmonary Bypass” Circulation 2008, 117: e170-e170. DOI: 10.1161/circulationaha.107.752386.
- Mineralocorticoid antagonists in heart failure and chronic renal failure.Brown, N.J. Mineralocorticoid antagonists in heart failure and chronic renal failure. In Sodium in hHealth and Disease, ed. M. Burnier, Informa Healthcare, New York, NY, 2008, pp. 433-446.
- Tissue renin-angiotensin systems.Brown, N.J. Tissue renin-angiotensin systems. In Hypertension Primer, 4th edition eds. J.L. Izzo, D. Sica, and H.R. Black, Lippincott Williams and Wilkins, Philadelphia, PA, 2008, pp. 59-60.
- Response to Interleukin-6 Antagonists for the Management of HypertensionLuther J, Brown N. Response to Interleukin-6 Antagonists for the Management of Hypertension Hypertension 2007, 49: e19. DOI: 10.1161/01.hyp.0000257806.83296.e4.
- Nancy J. Brown, M.D., Robert H. Williams Professor of Medicine and Pharmacology.Brown, N.J. Chapter 1: Nancy J. Brown, M.D., Robert H. Williams Professor of Medicine and Pharmacology. In What’s Past is Prologue, ed. Eric Neilson, Hillsboro Press, Franklin, TN, 2006, pp. 3-8.
- RISK FACTOR INTERACTIONS AND GENETIC EFFECTS ASSOCIATED WITH POST-OPERATIVE ATRIAL FIBRILLATIONMOTSINGER A, DONAHUE B, BROWN N, RODEN D, RITCHIE M. RISK FACTOR INTERACTIONS AND GENETIC EFFECTS ASSOCIATED WITH POST-OPERATIVE ATRIAL FIBRILLATION 2005, 584-595. DOI: 10.1142/9789812701626_0054.
- Aldosterone and end-organ damageBrown N. Aldosterone and end-organ damage Current Opinion In Internal Medicine 2005, 4: 381-387. DOI: 10.1097/00132980-200508000-00009.
- Erratum to “Characterization of the CYP4A11 gene, a second CYP4A gene in humans” [Arch. Biochem. Biophys. 409 (2003) 221–227]Bellamine A, Wang Y, Waterman M, Gainer J, Dawson E, Brown N, Capdevila J. Erratum to “Characterization of the CYP4A11 gene, a second CYP4A gene in humans” [Arch. Biochem. Biophys. 409 (2003) 221–227] Archives Of Biochemistry And Biophysics 2003, 412: 153. DOI: 10.1016/s0003-9861(03)00066-3.
- Contribution of bradykinin to the cardioprotective effects of ACE inhibitors.Murphey, L.J., D.E. Vaughan, and N.J. Brown. Contribution of bradykinin to the cardioprotective effects of ACE inhibitors. European Heart Journal 2003, 5:A37-A41.
- Antihypertensive agents and the drug therapy of hypertension.Brown, N.J., and J.A. Oates. Antihypertensive agents and the drug therapy of hypertension. In Goodman and Gillman’s The Pharmacological Basis of Therapeutics, 10th edition, eds. J.G. Hardman and L.E. Limbird, McGraw-Hill, 2001, pp. 871-900.
- Histamine, bradykinin, and their antagonists.Roberts, J.A., and N.J. Brown. Histamine, bradykinin, and their antagonists. In Goodman and Gillman’s The Pharmacological Basis of Therapeutics,10th edition, eds. J.G. Hardman and L.E. Limbird, McGraw-Hill, 2001, pp. 645-668.
- Synergistic Effect of Adrenal Steroids and Angiotensin II on Plasminogen Activator Inhibitor-1 ProductionBrown N, Kim K, Chen Y, Blevins L, Nadeau J, Meranze S, Vaughan D. Synergistic Effect of Adrenal Steroids and Angiotensin II on Plasminogen Activator Inhibitor-1 Production The Journal Of Clinical Endocrinology & Metabolism 2000, 85: 336-344. DOI: 10.1210/jcem.85.1.6305.
- α1A-Adrenergic receptor polymorphismXie H, Kim R, Stein C, Gainer J, Brown N, Wood A. α1A-Adrenergic receptor polymorphism Pharmacogenetics And Genomics 1999, 9: 651-656. DOI: 10.1097/01213011-199910000-00012.
- Role of Angiotensin II in Coagulation and FibrinolysisBrown N, Vaughan D. Role of Angiotensin II in Coagulation and Fibrinolysis Heart Failure Reviews 1999, 3: 193-198. DOI: 10.1023/a:1009757416302.
- Recurrent angiotensin-converting enzyme inhibitor--associated angioedemaBrown N. Recurrent angiotensin-converting enzyme inhibitor--associated angioedema JAMA 1997, 278: 232-233. DOI: 10.1001/jama.278.3.232.
- ReplyBrown N, Ray W, Snowden M, Griffin M. Reply Clinical Pharmacology & Therapeutics 1997, 61: 700-700. DOI: 10.1016/s0009-9236(97)90107-7.
- Plasminogen actiwator inhibitor type 1 in diabetes and hypertensionLitchfield W, Brown N, Vaughan D. Plasminogen actiwator inhibitor type 1 in diabetes and hypertension Current Opinion In Endocrinology Diabetes And Obesity 1997, 4: 233-238. DOI: 10.1097/00060793-199706000-00009.
- Plasminogen activator inhibitor type 1 in diabetes and hypertension.Litchfield, W.R., N.J. Brown, and D.E. Vaughan. Plasminogen activator inhibitor type 1 in diabetes and hypertension. Current Opinion in Endocrinology, Diabetes, and Obesity 1997, 4:233-238.